Matthew Lamb

Matthew Lamb, PharmD, RPh, is a senior leader in drug development with over 25 years of experience in global development and commercialization across biotechnology, specialty, and large-cap biopharma companies, including Roche, Actavis, Celgene, and Bristol Myers Squibb. He has worked across all phases of drug development and commercialization, from pre-IND through to clinical trials (Phase I–III) and post-marketing lifecycle management.

Therapeutic areas where Matt has development expertise include transplantation, immunology, oncology, neuroscience, virology, gastroenterology, and women’s health. Matt has made significant contributions to the global registration of multiple innovative medicines, including Sotyktu™, Zeposia®, Otezla®, Delzicol®, Atelvia®, Tamiflu®, Actemra/RoActemra®, Invirase®, Pegasys®, and Copegus®.

Trained as a clinical pharmacologist, Matt also has extensive experience in global regulatory affairs and R&D project and portfolio management. In recent roles, he has overseen therapeutic area drug development and program leadership. He earned both his BS and PharmD from the Philadelphia College of Pharmacy and Science and completed a post-doctoral fellowship in clinical pharmacokinetics and pharmacodynamics at the University of North Carolina at Chapel Hill.